Product Information
DOXYLAMINE-PYRIDOXINE 10-10 MG is a generic product labeled by Endo USA Inc., priced at $1.0916 per EA under NDC 49884018601. Its NADAC has been published 347 times since Feb 12, 2020.
FDA first approved this application on Dec 6, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
DOXYLAMINE-PYRIDOXINE 10-10 MG
Doxylamine Succinate and Pyridoxine Hydrochloride, Delayed release Tablets 10 mg/10 mgStrength
10; 10 mg/1; mg/1
Manufacturer
Endo USA Inc.NDC
49884018601
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA208518FDA Approved
12/6/2017
TE Code
AB
On Market Since
12/19/2019
Pharmacological Classes
Price Statistics
The NADAC for DOXYLAMINE-PYRIDOXINE 10-10 MG has been published 347 times since Feb 12, 2020, and over the history we have for it it has declined 75.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0916 per EA |
|---|---|
| All-time high | $5.3468 (Sep 15, 2021) |
| All-time low | $0.9736 (Jul 17, 2024) |
| 52-week high | $1.3056 |
| 52-week low | $1.0916 |
| Median price | $2.0427 |
| Average price | $2.4468 |
| Largest weekly change | +68.5% (Jun 19, 2024) |
| Weeks tracked | 347 |
| Tracking since | Feb 12, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Doxylamine Succinate and Pyridoxine Hydrochloride, Delayed release Tablets 10 mg/10 mg market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Doxylamine Succinate and Pyridoxine Hydrochloride, Delayed release Tablets 10 mg/10 mg market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antihistamine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXYLAMINE-PYRIDOXINE 10-10 MG?
The current National Average Drug Acquisition Cost (NADAC) for DOXYLAMINE-PYRIDOXINE 10-10 MG, manufactured by Endo USA Inc., is $1.0916 per EA (NDC 49884018601), effective Sep 30, 2026.
How has the price of DOXYLAMINE-PYRIDOXINE 10-10 MG changed over time?
Over the history we have for it, the NADAC for DOXYLAMINE-PYRIDOXINE 10-10 MG has declined 75.7%. It has been tracked across 347 weekly CMS publications since Feb 12, 2020.
What are the highest and lowest recorded NADAC prices for DOXYLAMINE-PYRIDOXINE 10-10 MG?
Since Feb 12, 2020, the NADAC for DOXYLAMINE-PYRIDOXINE 10-10 MG has ranged from a low of $0.9736 (Jul 17, 2024) to a high of $5.3468 (Sep 15, 2021), with a median of $2.0427 per EA.
Are there cheaper alternatives to DOXYLAMINE-PYRIDOXINE 10-10 MG?
No other NADAC-published product currently shares the active ingredient and strength of DOXYLAMINE-PYRIDOXINE 10-10 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXYLAMINE-PYRIDOXINE 10-10 MG?
DOXYLAMINE-PYRIDOXINE 10-10 MG (NDC 49884018601) is labeled by Endo USA Inc., and CMS classifies it as a generic product.